.
MergerLinks Header Logo

Announced

Completed

Agilent completed the acquisition of Resolution Bioscience for $695m.

Financials

Edit Data
Transaction Value£394m
Consideration TypeContingent Deferred Consideration, Cash
Capital Owned-
Capital Bid For100%
EV/Sales16x
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Completed

Acquisition

Friendly

treatment development

Private

Single Bidder

United States

cancer treatment

Biotechnology

Domestic

Majority

Synopsis

Edit

Agilent, an American analytical instrumentation development and manufacturing company, completed the acquisition of Resolution Bioscience, a cancer diagnostics solutions provider, for $695m. "The Resolution Bioscience team and powerful technology are strategic and important additions to Agilent’s growing business in precision oncology solutions. This also accelerates our work to more broadly deliver precision oncology testing for patients worldwide with NGS-based diagnostic kits. We’re excited to have Resolution Bioscience joining with us to expand our work in the fight against cancer," Mike McMullen, Agilent President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US